ATROPINE

For topical ocular use. The depth of the angle of the anterior chamber should be assessed before the product is used.

Adults Refraction:

One or two drops to be instilled into the eye(s) one hour before refracting Uveitis / iritis: One or two drops to be instilled into the eye(s) to a maximum of 4 times daily. Elderly Mydriatics and cycloplegics should only be used with caution in the elderly and others who may have raised intra ocular pressure Children Refraction: One drop to be instilled into each eye twice daily for 1 - 3 days prior to the examination Uveitis / iritis: One drop to be instilled into each eye to a maximum of 3 times daily

Patients may experience photophobia and eyes should be protected from bright light while the pupils are dilated. Prolonged use of atropine eye drops may lead to local irritation, transient stinging, hyperaemia, oedema and conjunctivitis.

An increase in intra-ocular pressure may occur, especially in patients with closed angle glaucoma. Hypersensitivity to atropine is not uncommon and may appear as a skin rash or conjunctivitis. Systemic toxicity may be produced by the instillation of the eye drops especially in infants and the elderly.

Reported symptoms include severe ataxia, restlessness, excitement and hallucinations. Other adverse effects may include a dry mouth with difficulty in swallowing and talking, flushing and a dry skin, transient bradycardia followed by tachycardia, palpitations and arrhythmias, reduced bronchial secretions, urinary urgency and retention and constipation.

Side effects that occur occasionally include confusion (particularly in the elderly), nausea, vomiting and giddiness Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

It should only be used with caution in patients who may have raised intra ocular pressure. The product contains benzalkonium chloride solution which may cause eye irritation and soft contact lenses must not be worn during the period of use.

Patients should be warned that antimuscarinic eye drops will temporarily impair vision. Patients should wash hands after using the eye drops and great care should be taken to avoid getting the product into the mouth. Due to the risk of provoking hyperpyrexia, atropine should only be used with great caution when the ambient temperature is high or the patient has a fever.

Care is also required in patients with conditions characterised by tachycardia. Darkly pigmented iris is more resistant to pupillary dilation and caution should be exercised to avoid overdosage. The eye drops should be discarded 30 days after first opening.

During use, care should be taken not to touch the dropper nozzle on to the eyelid or any other surface. The product is for external use only and should be stored out of the sight and reach of children. This medicine contains less than 1 mmol sodium (23 mg) per drop, that is to say essential ‘sodium-free’.

The medicine contains 0,633mg phosphates.

For topical ocular use. The depth of the angle of the anterior chamber should be assessed before the product is used.

Adults Refraction:

One or two drops to be instilled into the eye(s) one hour before refracting Uveitis / iritis: One or two drops to be instilled into the eye(s) to a maximum of 4 times daily. Elderly Mydriatics and cycloplegics should only be used with caution in the elderly and others who may have raised intra ocular pressure Children Refraction: One drop to be instilled into each eye twice daily for 1 - 3 days prior to the examination Uveitis / iritis: One drop to be instilled into each eye to a maximum of 3 times daily